Jerrell Shelton, President and CEO of Cryoport, Inc. (NASDAQ: CYRX), executed a sale of 7,918 shares of the companys common stock on March 16, 2026, at a price of $8.00 per share. The transaction generated total proceeds of $63,344 and, according to a Form 4 filing with the Securities and Exchange Commission, was conducted to cover taxes owed upon the vesting of restricted stock rights in line with company policy.
After the sale, Shelton directly holds 1,054,501 shares of Cryoport. Two days earlier, on March 14, 2026, Shelton also completed an acquisition of 492,901 shares through the exercise of stock options at an exercise price of $8.60. Those options are structured to vest monthly over a four-year period beginning April 14, 2026, and they carry an expiration date of March 14, 2033.
Market data around the transaction show Cryoport trading at $8.37, giving the company a market capitalization of $416.3 million. The shares have exhibited notable volatility, reflected in a beta of 1.74. Over the past 12 months the stock has risen 35 percent, despite some recent weakness.
In its most recent reported quarter, Q4 2025, Cryoport posted revenue of $45.45 million, topping analysts expectations of $42.93 million - a 5.87 percent surprise. However, profitability metrics lagged consensus: earnings per share were reported at negative $0.27, compared with an anticipated negative $0.21, a variance of 28.57 percent to the downside. While the revenue outperformance indicates continued topline momentum, the EPS shortfall highlights ongoing pressures on the companys bottom line.
An analysis referenced alongside the filing indicated the shares appear overvalued relative to a calculated Fair Value. The filing also notes availability of more detailed research on the company through proprietary reports covering US-listed stocks.
Summary and context
- Insider sale to cover taxes: The CEO sold a small portion of his holdings specifically to meet tax obligations tied to vesting restricted stock.
- Large option exercise: Shelton exercised 492,901 options with a strike of $8.60 that will vest monthly over four years and expire in 2033.
- Mixed quarterly results: Revenue exceeded estimates while EPS fell short, underscoring a divergence between sales performance and near-term profitability.
Impacted sectors
- Biotechnology and life sciences - Cryopreservation logistics and related services are core to Cryoports business model.
- Capital markets - Insider transactions and quarterly results can influence investor sentiment in small-cap healthcare names.
Key points
- Shelton sold 7,918 shares on March 16, 2026, at $8.00 each for $63,344 to cover taxes tied to vested restricted stock.
- Shelton directly owns 1,054,501 shares following the sale and exercised 492,901 options on March 14, 2026, at an $8.60 exercise price; those options vest monthly over four years from April 14, 2026 and expire March 14, 2033.
- Cryoport reported Q4 2025 revenue of $45.45 million versus expectations of $42.93 million, but EPS came in at -$0.27 versus an expected -$0.21.
Risks and uncertainties
- Profitability pressure - The EPS miss suggests ongoing challenges with costs or other operational levers that affect earnings, relevant to investors focused on margins in the biotech and logistics sectors.
- Valuation concerns - The cited analysis that the stock appears overvalued versus Fair Value introduces valuation risk for prospective buyers, particularly in a stock with elevated beta and recent price volatility.
- Market sensitivity - As a smaller-cap company with a beta of 1.74, Cryoports share price may be more sensitive to broader market swings and sector-specific developments, affecting liquidity and investor returns.